Zonisamide (Zonegran)



Excerpt from Cafer's Mood Stabilizers and Antiepileptics


  Zonisamide (ZONEGRAN)
 Pronunciation: zoe NIS a mide / ZAHN uh gran
 “Zone is mighty, Zone is grand”
Zonisamide (Zonegran) mascot by Jason Cafer MD cafermed
❖ Antiepileptic 
❖ Voltage-gated sodium channel blocker 
❖ Glutamate ⇩		FDA approved for:
❖ Focal seizures		Used off label for: 
❖ Other types of seizures 
❖ PTSD nightmares 
❖ Sleep-related eating disorder 
❖ Obesity 
❖ Binge eating disorder 
❖ Alcohol use disorder 
❖ Migraine prophylaxis 
❖ Parkinsonian symptoms associated with Lewy body dementia

 
Zonisamide (Zonegran) is a broad-spectrum antiepileptic drug (AED) that blocks sodium and calcium channels and increases dopaminergic and serotonergic transmission. It is unrelated to other antiseizure medications. 

Zonegran can cause weight loss:
Zonegran can cause weight loss by Jason Cafer MD (cafermed)
Zonisamide decreases appetite and has been shown to decrease binge-eating. Cognitive impairment including “brain fog”, confusion, difficulty concentrating, and word-finding difficulty are relatively common. It is not used as a mood stabilizer because it may cause irritability. There have been rare cases of zonisamide-induced psychosis.

 
Due to carbonic anhydrase inhibitor activity (although weak) there is a chance of kidney stones (4%) and metabolic acidosis. Aplastic anemia and agranulocytosis have been reported. Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) have been reported. Oligohidrosis (decreased ability to sweat) has occurred with children. 

 
Half-life is over 60 hours. About 30% is excreted unchanged in the urine.

Zonisamide has a sulfonamide structure. It is contraindicated in patients allergic to sulfa drugs. Other sulfonamides include the antibiotic sulfamethoxazole (Bactrim, Septra) and the  disease-modifying antirheumatic drug (DMARD) sulfasalazine.

Dosing: Start 100 mg daily. May increase by 100 mg q 2 weeks for a maximum of 600 mg. However, doses above 400 mg are rarely more effective. As with any antiepileptic medication, taper dose gradually to discontinue. 

Dynamic interactions: 
❖ Sedative (mild) 
❖ Hypokalemia 
❖ Metabolic acidosis 
❖ Decreased renal perfusion		Kinetic interactions:
❖ Kinetic interactions: 
❖ Urine alkalization (minor) 
❖ 3A4 substrate (minor)
Zonisamide (Zonegran) is a CYP3A4 substrate by Jason Cafer MD
Zonisamide (Zonegran) decreases lithium levels visual by jason cafer md

Zonegran pill picture cafermed







































Comments











Post a Comment























Popular posts from this blog









Pregabalin mascot & Black Friday Sale




















Image







Check out the Black Friday sale on Cafer's Psychopharmacology: Visualize to Memorize 270 Medication Mascots.  For a limited time, the paperback is $49.95  and the PDF version is $29.95  (regular price $89.95).  The PDF is formatted for ultra-rapid navigation with thousands of internal links. Included are medication mascots to assist you with memorization of trade name / generic name pairings. Here are excerpts from from 5-star Amazon reviews: ★★★★★ Love it I barely look at the pictures, honestly. I'm most impressed by the way the author explains everything through text, simply and efficiently. ★★★★★  GREAT PSYCH NO STUDENT EASY TO READ RESOURCE This breaks things down easily and is a great study resource for those needing something more concise and easier to read. ★★★★★  THIS BOOK helped me SO MUCH! First of all, I don’t write reviews but this book deserves it. I am in a CMHC graduate program where a class asked me to know most of the antipsychotics and antidepressants. It was ...








Read more










Solriamfetol (SUNOSI) 




















Image







 From Cafer's Psychopharmacology: Visualize to Memorize 270 Medication Mascots Solriamfetol (SUNOSI)   Solriamfetol (Sunosi) is a new wakefulness promoting medication that lasts for 9 hours. It is stimulating but not considered a “stimulant”. It is a norepinephrine and weak dopamine reuptake inhibitor. Sunosi could be conceptualized as an atypical antidepressant  with a mechanism similar bupropion (Wellbutrin). However, solriamfetol is not approved for depression, and clinical trials did not include psychiatric patients. About 1 in 25 subjects treated for narcolepsy/sleep apnea had psychiatric side effects such as irritability and anxiety. Solriamfetol is a Schedule IV controlled substance. By comparison, bupropion  is non-controlled but does have potential for abuse at high doses. Subjects who abused drugs reported “drug liking” similar to the appetite-suppressing stimulant phentermine (Adipex) when solriamfetol was taken at supratherapeutic dose. Phentermine is also Schedule...








Read more










Lumateperone (Caplyta)




















Image







Available on Amazon:  Cafer's Mood Stabilizers and Antiepileptic Drugs        Lumateperone (CAPLYTA) Pronunciation:  luma TEP er ohn / cap LIE ta  “’Lum inated  Cap lighter” Antipsychotics are represented  with spooky mascots. Year of US release: 2020  ❖ Antipsychotic (SGA) ❖ D2 antagonist - ⇩DA ❖ 5-HT2A antagonist - ⇧DA ❖ Glutamate modulator  FDA-approved for:  ❖ Schizophrenia  Lumateperone is a new antipsychotic that purportedly modulates glutamate  in addition to the usual SGA mechanism of blocking D2 and 5-HT2A receptors. However, the official prescribing information does not mention glutamate, suggesting the FDA saw insufficient evidence for lumateperone being a first-in-class novel antipsychotic. It appears to be equally effective as risperidone (Risperdal) with fewer side effects other than sedation (Citrome, 2016).  Lumateperone’s D2 receptor occupancy is lower than most other antipsychotics. This means extrapyramidal side effects are unlikely. The other anti...








Read more